Added to YB: 2026-06-16
Pitch date: 2026-06-11
NWBO [neutral]
Northwest Biotherapeutics, Inc.
-9.63%
current return
Author Info
No bio for this author
Company Info
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer.
Market Cap
$290.3M
Pitch Price
$0.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.78
P/E
-6.85
EV/Sales
164.06
Sector
Biotechnology
Category
special_situation
Conditional Approval For DCVax-L? - Northwest Biotherapeutics, Inc.
NWBO (overview): Speculative piece on DCVax-L MAA stuck in MHRA limbo past 900 days. Author argues outright rejection unlikely given lengthy review + proven efficacy/safety; conditional marketing approval (CMA) probable. CMA = revenue via NICE reimbursement, potential re-rating/uplisting, institutional interest, paves way for FDA/EU. Cons: extra study costs, short-seller spin. Rumored 1B+ naked short.
Read full article (4 min)